MCRB vs MIRM vs ARWR vs ACAD

For growth investors, Arrowhead Pharmaceuticals, Inc.

(ARWR) is the stronger pick with 232. 6% revenue growth year-over-year, versus 11. 9% for ACADIA Pharmaceuticals Inc. (ACAD). ACADIA Pharmaceuticals Inc. (ACAD) offers the better valuation at 9. 9x trailing P/E (50. 9x forward), making it the more compelling value choice. Analysts rate Seres Therapeutics, Inc. (MCRB) a "Buy" — based on 18 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, ACADIA Pharmaceuticals Inc.

(ACAD) is the cheapest at 9. 9x versus Seres Therapeutics, Inc. at 12. 1x.

Over the past 5 years, Mirum Pharmaceuticals, Inc.

(MIRM) delivered a total return of +451. 3%, compared to -98. 1% for Seres Therapeutics, Inc. (MCRB). Over 10 years, the gap is even starker: ARWR returned +1253% versus MCRB's -98. 5%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Mirum Pharmaceuticals, Inc.

(MIRM) is the lower-risk stock at 1. 02β versus Arrowhead Pharmaceuticals, Inc. 's 1. 81β — meaning ARWR is approximately 77% more volatile than MIRM relative to the S&P 500. On balance sheet safety, ACADIA Pharmaceuticals Inc. (ACAD) carries a lower debt/equity ratio of 4% versus 188% for Seres Therapeutics, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Arrowhead Pharmaceuticals, Inc.

(ARWR) is pulling ahead at 232. 6% versus 11. 9% for ACADIA Pharmaceuticals Inc. (ACAD). On earnings-per-share growth, the picture is similar: Seres Therapeutics, Inc. grew EPS 103. 4% year-over-year, compared to 68. 4% for ACADIA Pharmaceuticals Inc.. Over a 3-year CAGR, MIRM leads at 89. 1% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Seres Therapeutics, Inc.

(MCRB) is the more profitable company, earning 721. 9% net margin versus -4. 5% for Mirum Pharmaceuticals, Inc. — meaning it keeps 721. 9% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ARWR leads at 11. 9% versus -119. 1% for MCRB. At the gross margin level — before operating expenses — ARWR leads at 97. 1%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

Analyst consensus price targets imply the most upside for ACAD: 54.

1% to $34. 78.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Mirum Pharmaceuticals, Inc.

(MIRM) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1. 02), +679. 2% 10Y return). Seres Therapeutics, Inc. (MCRB) carries a higher beta of 1. 69 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (MIRM: +679. 2%, MCRB: -98. 5%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: MCRB is a small-cap deep-value stock; MIRM is a small-cap high-growth stock; ARWR is a mid-cap high-growth stock; ACAD is a small-cap deep-value stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.